Xuan Zhou

Impact Of Chronic Kidney Disease On The Pharmacodynamic And Pharmacokinetic Effects Of Ticagrelor In Patients With Diabetes Mellitus And Coronary Artery Disease.

L. Been, D. Angiolillo, F. Franchi, 2021, European heart journal. Cardiovascular pharmacotherapy.

Decrease in circulating myeloid dendritic cell precursors in patients with intracranial large artery atherosclerosis.

Xuan Zhou, Bing-Ling Li, Ni Zhang, 2015, International journal of clinical and experimental pathology.

Impact of Timing of Pharmacodynamic Assessment on Platelet Reactivity in Patients Treated With Cangrelor.

L. Been, D. Angiolillo, F. Franchi, 2021, JACC. Cardiovascular interventions.

Lack of association between genetic polymorphisms affecting autonomic activity and coronary artery spasm.

Xuan Zhou, Xuan Zhou, Ding-cheng Xiang, 2013, Biomedical and environmental sciences : BES.

Platelet P2Y12 inhibiting therapy in adjunct to vascular dose of rivaroxaban or aspirin: A pharmacodynamic study of dual pathway inhibition versus dual antiplatelet therapy.

L. Been, D. Angiolillo, T. Geisler, 2022, European heart journal. Cardiovascular pharmacotherapy.

Pharmacodynamic profiles of dual-pathway inhibition with or without clopidogrel vs dual antiplatelet therapy in patients with atherosclerotic disease

L. Been, D. Angiolillo, T. Geisler, 2022, Thrombosis and Haemostasis.

P2Y12 Inhibitor Monotherapy after Percutaneous Coronary Intervention

D. Angiolillo, L. Ortega‐Paz, Xuan Zhou, 2022, Journal of cardiovascular development and disease.

Myeloperoxidase G-463 A polymorphism and coronary artery disease susceptibility in the Chinese population : an updated meta-analysis and review

Xuan Zhou, Bing-Ling Li, Ni Zhang, 2016 .

Switching from Dual Antiplatelet Therapy with Aspirin Plus a P2Y 12 Inhibitor to Dual Pathway Inhibition with Aspirin Plus Vascular-Dose Rivaroxaban: The Switching Anti-Platelet and Anti-Coagulant Therapy (SWAP-AC) Study

L. Been, D. Angiolillo, F. Rollini, 2022, Thrombosis and Haemostasis.

Impact of evolocumab on the pharmacodynamic profiles of clopidogrel in patients with atherosclerotic cardiovascular disease: a randomised, double-blind, placebo-controlled study.

L. Been, D. Angiolillo, F. Rollini, 2023, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

P2Y12 Inhibitor Monotherapy after Percutaneous Coronary Intervention

D. Angiolillo, L. Ortega‐Paz, Xuan Zhou, 2022, Journal of cardiovascular development and disease.

Cangrelor in Patients with Coronary Artery Disease Pre-treated with Ticagrelor: The Switching Antiplatelet (SWAP)-5 Study.

L. Been, D. Angiolillo, F. Rollini, 2022, JACC. Cardiovascular interventions.

Switching from Dual Antiplatelet Therapy with Aspirin Plus a P2Y 12 Inhibitor to Dual Pathway Inhibition with Aspirin Plus Vascular-Dose Rivaroxaban: The Switching Anti-Platelet and Anti-Coagulant Therapy (SWAP-AC) Study

L. Been, D. Angiolillo, F. Rollini, 2023, Thrombosis and Haemostasis.